Formulation and in-vitro anticancer activity of nilotinib immediate release and ibrutinib sustained release pellets
Background: Blood cancer is a significant contributor to mortality rates worldwide, and its prevalence is projected to rise on a global scale. This trend places considerable strain on healthcare systems and necessitates the expedited development of innovative treatments by pharmaceutical firms to re...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Creative Pharma Assent,
2024-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|